Inventor · disambiguated record
Byoung S. Kwon
Also filed as: KWON BYOUNG S · KWON BYOUNG SE
38 granted patents·25 pending applications·1,242 citations·filing 1986–2024
98Inventor score
Files withEUTILEX CO LTD34NAT CANCER CT7UNIV INDIANA RES & TECH CORP5KWON BYOUNG SE3ADVANCED RES & TECH INST2
Top patents by PatentIndex Score
63 records- 0198US9309321B2Monoclonal antibody specifically recognizing an epitope for switching to Th17 cellNAT CANCER CT·Filed 2013·Granted Apr 12, 2016·30 cites·8 claims
- 0298US6974863B2Antibody for 4-1BBUNIV INDIANA RES & TECH CORP·Filed 2002·Granted Dec 13, 2005·170 cites·7 claims
- 0398US6569997B1Antibody specific for H4-1BBADVANCED RES & TECH INST·Filed 2000·Granted May 27, 2003·258 cites·8 claims
- 0497US9255151B2Antibody specifically recognizing an epitope for switching to TH1 cellNAT CANCER CT·Filed 2013·Granted Feb 9, 2016·24 cites·8 claims
- 0597US6905685B2Methods of using antibodies to human receptor protein 4-1BBFiled 2001·Granted Jun 14, 2005·141 cites·8 claims
- 0697US6303121B1Method of using human receptor protein 4-1BBADVANCED RES AND TECHNOLOGY·Filed 1998·Granted Oct 16, 2001·219 cites·14 claims
- 0796US10174122B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2018·Granted Jan 8, 2019·23 cites·15 claims
- 0896US9255152B2Antibody specifically recognizing an epitope for switching to Th2 cell and a method for converting T cell to type 2 helper T cell using the sameNAT CANCER CT·Filed 2013·Granted Feb 9, 2016·24 cites·5 claims
- 0995US9862775B2Monoclonal antibody which specifically recognizes B cell lymphoma and use thereofEUTILEX CO LTD·Filed 2015·Granted Jan 9, 2018·15 cites·9 claims
- 1094US6362325B1Murine 4-1BB geneADVANCED RES & TECH INST·Filed 1993·Granted Mar 26, 2002·129 cites·7 claims
- 1193US7829088B2Composition comprising humanized antibody HBBK4 for the treatment of cancer and the use thereofUNIV ULSAN FOUND FOR IND COOP·Filed 2006·Granted Nov 9, 2010·24 cites·4 claims
- 1290US10233254B2Monoclonal antibody which specifically recognizes B cell lymphoma and use thereofEUTILEX CO LTD·Filed 2017·Granted Mar 19, 2019·4 cites·18 claims
- 1390US7932045B2Method of isolating and proliferating autologous antigen-specific CD8+ T cell using anti-4-1BB antibodiesUNIV ULSAN FOUND FOR IND COOP·Filed 2008·Granted Apr 26, 2011·18 cites·13 claims
- 1487US6355476B1Nucleic acid encoding MIP-1α LymphokineADVANCED RES AND TECHNOLOGYINC·Filed 1992·Granted Mar 12, 2002·85 cites·4 claims
- 1584US10919972B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2018·Granted Feb 16, 2021·1 cites·2 claims
- 1684US10626183B2IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereofEUTILEX CO LTD·Filed 2019·Granted Apr 21, 2020·2 cites·30 claims
- 1783US11013765B2Chimeric antigen receptor that binds HLA-DR and CAR-T cellEUTILEX CO LTD·Filed 2019·Granted May 25, 2021·2 cites·15 claims
- 1883US10774151B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2020·Granted Sep 15, 2020·1 cites·5 claims
- 1983US8026353B2Nucleic acid molecules encoding human 4-1BBUNIV INDIANA RES & TECH CORP·Filed 2001·Granted Sep 27, 2011·6 cites·4 claims
- 2082US10919976B2IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereofEUTILEX CO LTD·Filed 2019·Granted Feb 16, 2021·1 cites·4 claims
- 2180US10801011B2Methods for isolating and proliferating autologous cancer antigen-specific CD8+ T cellsEUTILEX CO LTD·Filed 2017·Granted Oct 13, 2020·1 cites·8 claims
- 2279US10570371B2Methods for isolating and proliferating autologous cancer antigen-specific CD8+T cellsEUTILEX CO LTD·Filed 2018·Granted Feb 25, 2020·1 cites·15 claims
- 2378US10927183B2Anti-human VSIG4 antibodies and uses thereofEUTILEX CO LTD·Filed 2020·Granted Feb 23, 2021·1 cites·28 claims
- 2475US2024350542A1Anticancer t cell therapy product-assisting composition comprising depleting anti-cd4 monoclonal antibody and use thereofNAT CANCER CT·Filed 2024·Application pending·0 cites
- 2574US11053298B2Epitope for switching to TH2 cell and use thereofEUTILEX CO LTD·Filed 2018·Granted Jul 6, 2021·0 cites·7 claims
- 2674US8445643B2Anti-IRC85 monoclonal antibody; and composition comprising the same for preventing and treating tuberculosis or enteritis disease; and the use thereofKWON BYOUNG SE·Filed 2008·Granted May 21, 2013·2 cites·5 claims
- 2773US11859004B2Anti-human 4-1BB antibodies and uses thereofEUTILEX CO LTD·Filed 2021·Granted Jan 2, 2024·0 cites·8 claims
- 2873US11072646B2Epitope for switching to TH1 cell and use thereofEUTILEX CO LTD·Filed 2018·Granted Jul 27, 2021·0 cites·6 claims
- 2973US10851151B2Epitope for switching to TH17 cell and use thereofEUTILEX CO LTD·Filed 2017·Granted Dec 1, 2020·0 cites·17 claims
- 3072US5679511ACDNA clones for a regulatory protein in the melanin-production pathwayDONALD GUTHRIE FOUNDATION FOR·Filed 1992·Granted Oct 21, 1997·35 cites·6 claims
- 3170US2024101678A1Hla-dr car-t compositions and methods of making and using the sameEUTILEX CO LTD·Filed 2023·Application pending·0 cites
- 3269US11396555B2Monoclonal antibody which specifically recognizes B cell lymphoma and use thereofEUTILEX CO LTD·Filed 2019·Granted Jul 26, 2022·0 cites·11 claims
- 3365US2021277139A1Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereofEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 3464US11951130B2Chimeric antigen receptor that binds HLA-DR and CAR-T cellEUTILEX CO LTD·Filed 2021·Granted Apr 9, 2024·0 cites·20 claims
- 3564US11905334B2Anti-human VSIG4 antibodies and uses thereofEUTILEX CO LTD·Filed 2021·Granted Feb 20, 2024·0 cites·15 claims
- 3663US11395836B2Cancer antigen specific cytotoxic T cellEUTILEX CO LTD·Filed 2019·Granted Jul 26, 2022·0 cites·14 claims
- 3762US4898814AA cDNA clone for human tyrosinaseDONALD GUTHRIE FOUNDATION FOR·Filed 1986·Granted Feb 6, 1990·25 cites·6 claims
- 3862US2016244503A1Novel Epitope for Switching to Th17 Cell and Use ThereofNAT CANCER CT·Filed 2016·Application pending·0 cites
- 3962US2021169930A1Anticancer t cell therapy product-assisting composition comprising depleting anti-cd4 monoclonal antibody and use thereofNAT CANCER CT·Filed 2019·Application pending·0 cites
- 4060US2008312418A1Antibody Specific for Human 4-1BB ReceptorUNIV INDIANA RES & TECH CORP·Filed 2007·Application pending·0 cites
- 4160US2021401885A1Cancer antigen specific cytotoxic t cellEUTILEX CO LTD·Filed 2021·Application pending·0 cites
- 4259US2008008716A1Combined Pharmaceutical Composition Comprising an Anti-4-1BB Monoclonal Antibody and Chemotherapeutic Anti-Cancer Agent for Preventing and Treating Cancer DiseaseULSAN IND EDUCATION FOUNDATION·Filed 2007·Application pending·0 cites
- 4358US2007117161A1Antibody Specific for Human 4-1BB ReceptorUNIV INDIANA RES & TECH CORP·Filed 2006·Application pending·0 cites
- 4457US2006029595A1Methods of using human receptor protein 4-1BBUNIV INDIANA RES & TECH CORP·Filed 2005·Application pending·0 cites
- 4557US2016024177A1Novel Epitope for Switching to TH1 Cell and Use ThereofKWON BYOUNG SE·Filed 2015·Application pending·0 cites
- 4657US2016046691A1Novel Epitope for Switching to TH2 Cell and Use ThereofKWON BYOUNG SE·Filed 2015·Application pending·0 cites
- 4755US12331116B2Bispecific epitope binding protein comprising anti-4-1BB antibody and a PD-1 protein or fragments thereof and use thereofEUTILEX CO LTD·Filed 2022·Granted Jun 17, 2025·0 cites·27 claims
- 4854US12122845B2Anti-HER2/anti-4-1BB bispecific antibodies and uses thereofEUTILEX CO LTD·Filed 2021·Granted Oct 22, 2024·0 cites·25 claims
- 4954US2020138859A1Har-nds-derived stem cells, method for separating same, and use thereofEUTILEX CO LTD·Filed 2019·Application pending·0 cites
- 5053US2007253961A1Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid ArthritisULSAN IND EDUCATION FOUNDATION·Filed 2003·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Byoung S. Kwon files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →